New weekly injection shows promise for obesity – phase 2 trial complete

NCT ID NCT07177469

Completed Disease control Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new weekly injection called UBT251 in 205 overweight or obese adults to see if it helps with weight loss. Participants received different doses of the drug or a placebo for 24 weeks. The main goal was to measure the percentage change in body weight, with additional checks on waist size, BMI, and blood fats. The trial is now complete, and results will help decide if larger studies are needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UBT251 injection (a weekly shot for weight loss)
What this could lead to: If successful, this could lead to a new weekly injection option for managing obesity and related health issues like high blood pressure or fatty liver.
What could go wrong: This is an early Phase 2 study with only 205 people, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY &AMP; OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY &AMP; OVERWEIGHT

Contacts and locations

Locations

The Second Xiangya Hospital of Central South University

Changsha, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.